We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · September 13, 2022

Efficacy and Safety of Upadacitinib Treatment for Moderate to Severe Atopic Dermatitis in Real-World Practice in Japan

The Journal of Dermatology

 

Additional Info

The Journal of Dermatology
The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan
J Dermatol 2022 Aug 19;[EPub Ahead of Print], T Hagino, H Saeki, N Kanda

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading